GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Synthorx Inc (NAS:THOR) » Definitions » ROA %

Synthorx (Synthorx) ROA % : -28.99% (As of Sep. 2019)


View and export this data going back to 2018. Start your Free Trial

What is Synthorx ROA %?

ROA % is calculated as Net Income divided by its average Total Assets over a certain period of time. Synthorx's annualized Net Income for the quarter that ended in Sep. 2019 was $-48.86 Mil. Synthorx's average Total Assets over the quarter that ended in Sep. 2019 was $168.53 Mil. Therefore, Synthorx's annualized ROA % for the quarter that ended in Sep. 2019 was -28.99%.

The historical rank and industry rank for Synthorx's ROA % or its related term are showing as below:

THOR's ROA % is not ranked *
in the Biotechnology industry.
Industry Median: -35.41
* Ranked among companies with meaningful ROA % only.

Synthorx ROA % Historical Data

The historical data trend for Synthorx's ROA % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Synthorx ROA % Chart

Synthorx Annual Data
Trend Dec16 Dec17 Dec18
ROA %
-68.37 -129.37 -57.77

Synthorx Quarterly Data
Dec16 Dec17 Mar18 Jun18 Sep18 Dec18 Mar19 Jun19 Sep19
ROA % Get a 7-Day Free Trial Premium Member Only -147.61 -89.47 -23.04 -27.59 -28.99

Competitive Comparison of Synthorx's ROA %

For the Biotechnology subindustry, Synthorx's ROA %, along with its competitors' market caps and ROA % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Synthorx's ROA % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Synthorx's ROA % distribution charts can be found below:

* The bar in red indicates where Synthorx's ROA % falls into.



Synthorx ROA % Calculation

Synthorx's annualized ROA % for the fiscal year that ended in Dec. 2018 is calculated as:

ROA %=Net Income (A: Dec. 2018 )/( (Total Assets (A: Dec. 2017 )+Total Assets (A: Dec. 2018 ))/ count )
=-56.609/( (4.469+191.506)/ 2 )
=-56.609/97.9875
=-57.77 %

Synthorx's annualized ROA % for the quarter that ended in Sep. 2019 is calculated as:

ROA %=Net Income (Q: Sep. 2019 )/( (Total Assets (Q: Jun. 2019 )+Total Assets (Q: Sep. 2019 ))/ count )
=-48.864/( (173.393+163.671)/ 2 )
=-48.864/168.532
=-28.99 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual ROA %, the net income of the last fiscal year and the average total assets over the fiscal year are used. In calculating the quarterly data, the Net Income data used here is four times the quarterly (Sep. 2019) net income data. ROA % is displayed in the 30-year financial page.


Synthorx  (NAS:THOR) ROA % Explanation

ROA % measures the rate of return on the total assets (shareholder equity plus liabilities). It measures a firm's efficiency at generating profits from shareholders' equity plus its liabilities. ROA % shows how well a company uses what it has to generate earnings. ROA %s can vary drastically across industries. Therefore, ROA % should not be used to compare companies in different industries. For retailers, a ROA % of higher than 5% is expected. For example, Wal-Mart (WMT) has a ROA % of about 8% as of 2012. For banks, ROA % is close to their interest spread. A bank’s ROA % is typically well under 2%.

Similar to ROE, ROA % is affected by profit margins and asset turnover. This can be seen from the Du Pont Formula:

ROA %(Q: Sep. 2019 )
=Net Income/Total Assets
=-48.864/168.532
=(Net Income / Revenue)*(Revenue / Total Assets)
=(-48.864 / 0)*(0 / 168.532)
=Net Margin %*Asset Turnover
=N/A %*0
=-28.99 %

Note: The Net Income data used here is four times the quarterly (Sep. 2019) net income data. The Revenue data used here is four times the quarterly (Sep. 2019) revenue data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Be Aware

Like ROE, ROA % is calculated with only 12 months data. Fluctuations in the company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective. ROA % can be affected by events such as stock buyback or issuance, and by goodwill, a company's tax rate and its interest payment. ROA % may not reflect the true earning power of the assets. A more accurate measurement is ROC % (ROC).

Many analysts argue the higher return the better. Buffett states that really high ROA % may indicate vulnerability in the durability of the competitive advantage.

E.g. Raising $43b to take on KO is impossible, but $1.7b to take on Moody's is. Although Moody's ROA % and underlying economics is far superior to Coca Cola, the durability is far weaker because of lower entry cost.


Synthorx ROA % Related Terms

Thank you for viewing the detailed overview of Synthorx's ROA % provided by GuruFocus.com. Please click on the following links to see related term pages.


Synthorx (Synthorx) Business Description

Comparable Companies
Traded in Other Exchanges
N/A
Address
11099 North Torrey Pines Road, Suite 290, La Jolla, CA, USA, 92037
Executives
Powell Andrew Kenneth William director C/O COLLAGENEX PHARMACEUTICALS, INC., 41 UNIVERSITY DRIVE, NEWTOWN PA 18940
Ra Capital Healthcare Fund Lp 10 percent owner 200 BERKELEY STREET, 18TH FLOOR, BOSTON MA 02116
Ra Capital Management, L.p. 10 percent owner 200 BERKELEY STREET, 18TH FLOOR, BOSTON MA 02116
Peter Kolchinsky director, 10 percent owner 200 BERKELEY STREET, 18TH FLOOR, BOSTON MA 02116
Peter A. Thompson director, 10 percent owner C/O ANTHERA PHARMACEUTICALS, INC., 25801 INDUSTRIAL BOULEVARD, SUITE B, HAYWARD CA 94545
Vickie L Capps director 2985 SCOTT STREET, VISTA CA 92083
Rajeev M. Shah 10 percent owner 200 BERKELEY STREET, 18TH FLOOR, BOSTON MA 02116
Jay Lichter director C/O ARATANA THERAPEUTICS, INC., 11400 TOMAHAWK CREEK PARKWAY, SUITE 340, LEAWOOD KS 66211
Laura Shawver director, officer: President and CEO 1255 CRESCENT GREEN DRIVE, SUITE 250, CARY NC 27518
Avalon Ventures X, L.p. 10 percent owner 1134 KLINE STREET, LA JOLLA CA 92037
Orbimed Advisors Llc director, 10 percent owner 601 LEXINGTON AVENUE, 54TH FLOOR, NEW YORK NY 10022
Orbimed Capital Gp Vii Llc 10 percent owner 601 LEXINGTON AVENUE, 54TH FLOOR, NEW YORK NY 10022